Novartis News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

25.01.17	Press Release: Novartis delivered solid 2016 -5- (Dow Jones)
25.01.17	Press Release: Novartis delivered solid 2016 -4- (Dow Jones)
06.01.17	Press Release: Novartis invests in next -2- (Dow Jones)
06.01.17	Press Release: Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders (Dow Jones)
20.12.16	Press Release: Novartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc. (Dow Jones)
19.12.16	Press Release: Novartis announces exclusive -2- (Dow Jones)
19.12.16	Press Release: Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases (Dow Jones)
16.12.16	Press Release: Novartis receives positive CHMP -2- (Dow Jones)
16.12.16	Press Release: Novartis receives positive CHMP recommendation for Ilaris(R) to treat rare diseases in adults and children called Periodic Fever Syndromes (Dow Jones)
16.12.16	Press Release: Novartis drug Votubia(R) -2- (Dow Jones)
16.12.16	Press Release: Novartis drug Votubia(R) recommended by CHMP for EU approval to treat refractory partial-onset seizures in patients with TSC (Dow Jones)
16.12.16	Press Release: Novartis bolsters innovative -2- (Dow Jones)
16.12.16	Press Release: Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited (Dow Jones)
12.12.16	GlobeNewswire/Novartis lance SMS for Life 2.0 au -2- (Dow Jones)
12.12.16	GlobeNewswire/Novartis lance SMS for Life 2.0 au Nigeria pour aider à améliorer l'accès aux médicaments essentiels (Dow Jones)
12.12.16	Press Release: Novartis launches SMS for Life 2.0 -2- (Dow Jones)
12.12.16	Press Release: Novartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines (Dow Jones)
12.12.16	Press Release: Novartis provides update on -2- (Dow Jones)
12.12.16	Press Release: Novartis provides update on -2- (Dow Jones)
12.12.16	Press Release: Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD o... (Dow Jones)
12.12.16	Press Release: Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD o... (Dow Jones)
09.12.16	Press Release: Novartis LEE011 (ribociclib) plus -2- (Dow Jones)
09.12.16	Press Release: Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced brea... (Dow Jones)
08.12.16	Press Release: Novartis' Ultibro(R) Breezhaler(R) -2- (Dow Jones)
08.12.16	Press Release: Novartis' Ultibro(R) Breezhaler(R) improved lung function and COPD symptoms after direct switch from previous treatment (Dow Jones)
07.12.16	Press Release: Novartis' Lucentis(R) received EU -2- (Dow Jones)
07.12.16	Press Release: Novartis' Lucentis(R) received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions (Dow Jones)
06.12.16	Press Release: Novartis announces Zykadia(R) -2- (Dow Jones)
06.12.16	Press Release: Novartis announces Zykadia(R) first-line study results showing 16.6 month progression-free survival in patients with ALK+ advanced NSCLC (Dow Jones)
05.12.16	Press Release: Novartis data shows Treatment-free -2- (Dow Jones)
05.12.16	Press Release: Novartis data shows Treatment-free Remission rates are consistently above 50% regardless of reason for switch to Tasigna(R) from Glivec(R) (Dow Jones)
05.12.16	Press Release: Novartis survey uncovers -2- (Dow Jones)
05.12.16	Press Release: Novartis survey uncovers real-world burden of myeloproliferative neoplasms (rare blood cancers) on daily activity and ability to work (Dow Jones)
05.12.16	Press Release: Novartis: New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product (Dow Jones)
04.12.16	Press Release: Novartis presents results from -2- (Dow Jones)
04.12.16	Press Release: Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL (Dow Jones)
03.12.16	Press Release: Novartis SEG101 (crizanlizumab, -2- (Dow Jones)
03.12.16	Press Release: Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study (Dow Jones)
21.11.16	Press Release: Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD) (Dow Jones)
21.11.16	Press Release: Novartis commends publication of -2- (Dow Jones)
21.11.16	Press Release: Novartis commends publication of major report which recommends broad use of dual bronchodilators to treat COPD (Dow Jones)
18.11.16	Press Release: Innovative study with three -2- (Dow Jones)
18.11.16	Press Release: Innovative study with three treatment switches confirms Sandoz biosimilar etanercept has equivalent efficacy to originator (Dow Jones)
17.11.16	Press Release: Novartis announces AMG 334 significantly reduces monthly migraine days in second pivotal Phase III episodic migraine study (Dow Jones)
16.11.16	Press Release: Novartis announces AMG 334 -2- (Dow Jones)
16.11.16	Press Release: Novartis announces AMG 334 significantly reduces monthly migraine days in second pivotal Phase III episodic migraine study (Dow Jones)
16.11.16	Press Release: Novartis data at ASH and SABCS -2- (Dow Jones)
16.11.16	Press Release: Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer (Dow Jones)
15.11.16	Press Release: New analysis of Novartis' -2- (Dow Jones)
15.11.16	Press Release: New analysis of Novartis' Entresto(R) data shows long-term benefits on heart failure readmissions and total cardiovascular deaths (Dow Jones)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	71.14	1.54 %	K V
UBS Group	28.08	1.48 %	K V
Swiss Re	130.05	1.05 %	K V
Part Grp Hldg	1’266.00	0.96 %	K V
ABB	49.48	0.94 %	K V
Geberit	525.20	0.27 %	K V
Alcon	78.04	0.05 %	K V
Givaudan	3’868.00	-0.31 %	K V
CieFinRichemont	121.20	-0.57 %	K V
Sonova Hldg	301.00	-0.99 %	K V

mehr

12.07.24		Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an
12.03.24		MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis
31.01.24		Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung
12.06.23		Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch
25.04.23		Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an
07.12.22		MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert
19.07.22		Novartis-Aktie höher: Novartis bei nahezu stabilen Umsätzen mit Gewinnrückgang - Umbau soll 1,5 Milliarden US-Dollar Kosten sparen
06.05.22		Novartis-Aktie im Minus: Produktion von Krebsmitteln in Italien und USA ausgesetzt

12.07.24

Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an

12.03.24

MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis

31.01.24

Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung

12.06.23

Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch

25.04.23

Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an

07.12.22

MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert